Compugen

Company Overview

Snapshot

Founded in February 1993, Compugen operates with 51–200 employees. The company has raised a total of $141.92M across 7 funding rounds from 3 investors. In November 2021, Bristol-Myers Squibb Company invested in Compugen, highlighting continued strategic interest in its drug discovery and development efforts.

Business overview

Compugen is a clinical-stage drug discovery and development company focused on advancing a therapeutic pipeline primarily in early-stage immuno-oncology. The company utilizes a predictive-discovery infrastructure to identify novel drug targets, particularly immune checkpoint candidates, aimed at harnessing the immune system to combat cancer. Its product pipeline includes COM902/TIGIT, COM701/PVRIG, ILDR2/BAPOTULIMAB, and COM503/IL18-BP, addressing unmet medical needs in oncology. Compugen operates within the Health Tech & Life Sciences sector, with a specialization in Pharmaceuticals, serving patients and pharmaceutical companies.

Strategic signal

Compugen is actively engaging with the scientific community to showcase its latest research and clinical data. In October 2025, the company is scheduled to present at SITC 2025, and in September 2025, it will present research at the Single Cell Genomics 2025 Conference. These consistent presentations at key industry events signal ongoing scientific validation and a commitment to advancing its immuno-oncology programs, which is crucial for investor confidence in a clinical-stage biotechnology company.

Company Intelligence Q&A

What is Compugen's primary focus in drug discovery?

Compugen specializes in clinical-stage drug discovery and development, with a primary focus on immuno-oncology programs that utilize a predictive-discovery infrastructure to identify novel immune checkpoint candidates for cancer treatment.

When did Compugen last report its third-quarter financial results?

Compugen reported its third-quarter 2023 results on November 7, 2023.

What was a significant intellectual property expansion for Compugen in 2023?

In October 2023, Compugen expanded its intellectual property with a new Japanese patent for the triple combination of any Anti-PVRIG, TIGIT, and PD-1 antibody for the treatment of cancer.

What clinical data did Compugen present at SITC 2023?

In November 2023, Compugen presented new data at SITC 2023 suggesting the leading edge of its Anti-IL18 Binding Protein Antibody, COM503, in treating cancer.